TAM
FENC icon

Tucker Asset Management’s Fennec Pharmaceuticals FENC Stock Holding History

Tucker Asset Management’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-500
Closed -$4.16K – 1209
2023
Q1 		$4.16K Buy
+500
New +$4.64K ﹤0.01% 744

Other funds holding FENC

SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SGL
Sonic GP LLC Honolulu, Hawaii $45.4M AUM 5.08% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

Tucker Asset Management's FENC Position: Q2 2023 in Review

Tucker Asset Management sold out of Fennec Pharmaceuticals (FENC) in Q2 2023, closing a stake of 500 shares — an estimated $4.16K sold.

Tucker Asset Management first reported a position in FENC in Q1 2023 and held it in 1 quarter. The position peaked at $4.16K in Q1 2023. 56 funds tracked by Wall St. Rank hold FENC as of Q2 2023.

  • Tucker Asset Management reported no remaining Fennec Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Tucker Asset Management sold 500 Fennec Pharmaceuticals shares in Q2 2023, an estimated $4.16K.
  • Tucker Asset Management first reported a position in Fennec Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • Tucker Asset Management's Fennec Pharmaceuticals position peaked at $4.16K in Q1 2023.
  • 56 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q2 2023.

Based on Tucker Asset Management's 13F filing for Q2 2023, filed 8 Sep 2023.